HDAC9 and acute myeloid leukemia: We observed the HDAC inhibitors panobinostat and romidepsin to have potent activity across subtypes; these findings are consistent with our previous report with panobinostat13 and support the ongoing clinical evaluation (NCT02676323) of this drug for pediatric AML.